DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) shares crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $0.75 and traded as high as $0.81. DBV Technologies shares last traded at $0.76, with a volume of 60,495 shares traded.
Analyst Upgrades and Downgrades
DBVT has been the topic of a number of recent research reports. JMP Securities restated a "market outperform" rating and set a $5.00 target price on shares of DBV Technologies in a research note on Tuesday, September 24th. StockNews.com initiated coverage on shares of DBV Technologies in a report on Wednesday. They set a "hold" rating for the company. Finally, HC Wainwright upped their target price on shares of DBV Technologies from $5.00 to $7.00 and gave the stock a "buy" rating in a research report on Thursday, October 24th.
Read Our Latest Research Report on DBV Technologies
DBV Technologies Price Performance
The stock has a market capitalization of $74.31 million, a P/E ratio of -0.83 and a beta of 0.66. The company has a fifty day moving average of $0.75 and a two-hundred day moving average of $0.92.
Institutional Trading of DBV Technologies
An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. boosted its stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 6.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,568,909 shares of the company's stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies comprises about 0.2% of Yiheng Capital Management L.P.'s investment portfolio, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 71.74% of the company's stock.
DBV Technologies Company Profile
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Articles
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
